Click the “Start Activity” button to indicate you have reviewed the CME information for this activity.

Activity Speakers

James Ferrara, MD, DSc
Program Chair
Ward-Coleman Chair in Cancer Medicine
Professor and Director
Hematologic Malignancies Translational Research Center
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Motoko Koyama, MD, PhD
Senior Research Officer
Bone Marrow Transplantation Laboratory
QIMR, Berghofer Medical Research Institute
Brisbane, Australia

Ernst Holler, MD, PhD
Department of Hematology and Oncology
Blood and Marrow Transplantation Program
University of Regensburg
Regensburg, Germany


Release date: June 27, 2017
Expiration date: June 27, 2018

Program Overview

The goal of this educational program is to provide clinically relevant updates on the treatment of patients with hematologic malignancies likely to undergo allogeneic stem cell transplantation. The activity will focus on increasing clinician knowledge and the ability to integrate changes into practice to improve patient outcomes. The program will highlight the changes in treatment that acute Graft-Versus-Host-Disease (GVHD) is experiencing due to recent implications of clinical trials and breakthrough designations of target agents.

Learning Objectives
Upon successful completion of this educational activity, participants should be better able to:

  • Describe the overall clinical understanding of the pathophysiology, guidelines, and patient risk factors for GVHD
  • Evaluate novel treatment options, especially breakthrough therapies, for GVHD
  • Identify the importance of biomarkers for GVHD and the progress on finding more effective options

Target Audience

The intended audience for this activity is transplant specialists, oncologists, hematologists and other healthcare professionals involved in the treatment of patients with GVHD.

Accreditation Statement
The Medical College of Wisconsin is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This enduring material is approved for 1 year from the date of original release,  June 27, 2017 to June 27, 2018.

Faculty and Planner Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

James Ferrara, MD, DSc discloses that he has a GVHD biomarker patent from which he receives a royalty.

Motoko Koyama, MD, PhD has no relevant conflicts of interest to disclose.

Ernst Holler, MD, PhD discloses that he serves on the advisory board for Pharmacyclics. He also has received honoraria from Prime Oncology and Sanofi.

The educational content of this program has been peer reviewed by The Medical College of Wisconsin.

The Medical College of Wisconsin and Carden Jennings Publishing report the following relationship(s): No relevant financial relationships to disclose.

Signed disclosures are on file at The Medical College of Wisconsin.

Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

The material presented at or in any Medical College of Wisconsin or Carden Jennings Publishing Company, Ltd. continuing education activity does not necessarily reflect the views and opinions of Medical College of Wisconsin or Carden Jennings Publishing. Neither Medical College of Wisconsin or Carden Jennings Publishing, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME and Support Information
This continuing medical education activity is provided by The Medical College of Wisconsin. Collaborative Partner: Carden Jennings Publishing.

This activity is supported by educational grants from Incyte.

Click the “Start Activity” button to indicate you have reviewed the CME information for this activity.